[{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"f25984f7-928a-4db7-8a6a-64a803a17f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT02933736","created_at":"2021-01-18T14:24:13.882Z","updated_at":"2025-02-25T15:53:32.297Z","phase":"Phase 1","brief_title":"Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients","source_id_and_acronym":"NCT02933736","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CCND1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDKN2A deletion","tags":["CDKN2A • CCND1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-27"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"cb935a08-f353-4653-b5c2-b1bea0cd347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538572","created_at":"2022-09-14T18:56:05.720Z","updated_at":"2024-07-02T16:35:23.135Z","phase":"Phase 1","brief_title":"A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05538572","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B","pipe":" | ","alterations":" KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type","tags":["HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT3645"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"},{"id":"43035839-3bf9-43e5-bbd5-afd4d6d1337c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02981940","created_at":"2021-01-18T14:40:08.944Z","updated_at":"2024-07-02T16:35:41.812Z","phase":"Phase 2","brief_title":"A Study of Abemaciclib in Recurrent Glioblastoma","source_id_and_acronym":"NCT02981940","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B • CDK6","pipe":" | ","alterations":" CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type","tags":["CDKN2A • RB1 • CDK4 • CDKN2B • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-27"},{"id":"4d8abee9-1474-4364-a705-95320d1ba771","acronym":"ABORL","url":"https://clinicaltrials.gov/study/NCT03356223","created_at":"2021-01-18T16:34:03.658Z","updated_at":"2024-07-02T16:35:54.832Z","phase":"Phase 2","brief_title":"Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6","source_id_and_acronym":"NCT03356223 - ABORL","lead_sponsor":"Centre Leon Berard","biomarkers":" CDKN2A • CCND1","pipe":" | ","alterations":" CDKN2A deletion • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 11/05/2022","primary_completion_date":" 11/05/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-02-23"},{"id":"e0e1ee61-5bf4-4f29-bfd2-dc13f92d061d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04118036","created_at":"2021-01-18T20:07:39.336Z","updated_at":"2024-07-02T16:36:19.524Z","phase":"Phase 2","brief_title":"Abemaciclib + Pembrolizumab In Glioblastoma","source_id_and_acronym":"NCT04118036","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDKN2B • CASP3","pipe":" | ","alterations":" CDKN2A deletion • RB1 wild-type","tags":["CDKN2A • RB1 • CDKN2B • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Verzenio (abemaciclib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-12-14"},{"id":"bbe275ad-6be5-4313-a449-5847e6c48405","acronym":"CYCLIGIST","url":"https://clinicaltrials.gov/study/NCT01907607","created_at":"2021-01-18T08:35:33.854Z","updated_at":"2024-07-02T16:36:35.901Z","phase":"Phase 2","brief_title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","source_id_and_acronym":"NCT01907607 - CYCLIGIST","lead_sponsor":"Institut Bergonié","biomarkers":" KIT • CDKN2A • PDGFRA • ANO1","pipe":" | ","alterations":" CDKN2A deletion • PDGFRA mutation","tags":["KIT • CDKN2A • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2021-01-20"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"},{"id":"19be524b-4248-4054-97ea-82c45566fa0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02540876","created_at":"2021-01-18T12:17:34.359Z","updated_at":"2024-07-02T16:37:00.329Z","phase":"Phase 1","brief_title":"Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02540876","lead_sponsor":"University of Chicago","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A deletion • CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ilorasertib (ABT348)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/08/2015","start_date":" 09/08/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 02/08/2019","study_completion_date":" 02/08/2019","last_update_posted":"2019-04-22"}]